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Section 1: Introduction
During the past three decades, catheter and surgical ablation
of atrial ﬁbrillation (AF) have evolved from investigational
procedures to their current role as effective treatment options
for patients with AF. Surgical ablation of AF, using either
standard, minimally invasive, or hybrid techniques, is avail-
able in most major hospitals throughout the world. Catheter
ablation of AF is even more widely available, and is now
the most commonly performed catheter ablation procedure.1 Atrial ﬁbrillation deﬁnitions
sode An AF episode is deﬁned as AF that is do
and has a duration of at least 30 sec
monitoring tracing. The presence of s
by ECG monitoring between AF episod
ic AF Chronic AF has variable deﬁnitions and s
AF ablation.
ersistent AF Early persistent AF is deﬁned as AF that
F Lone AF is a historical descriptor that is p
of patients with AF undergoing AF ab
standing persistent AF Long-standing persistent AF is deﬁned
smal AF Paroxysmal AF is deﬁned as AF that term
nent AF Permanent AF is deﬁned as the presence
further attempts to restore or maintai
a therapeutic attitude on the part of t
attribute of AF. The term permanent A
with antiarrhythmic drug therapy or A
tent AF Persistent AF is deﬁned as continuous A
AF Silent AF is deﬁned as asymptomatic AF
5 atrial ﬁbrillation; ECG 5 electrocardiogram.Surgical AF Ablation was developed as a joint effort of the
Heart Rhythm Society (HRS), the European Heart Rhythm
Association (EHRA), and the European Cardiac
Arrhythmia Society (ECAS).1 The 2007 document was
also developed in collaboration with the Society of
Thoracic Surgeons (STS) and the American College of
Cardiology (ACC). This Consensus Statement on Catheter
and Surgical AF Ablation was rewritten in 2012 to reﬂect
the many advances in AF ablation that had occurred in the
interim.2 The rate of advancement in the tools, techniques,
and outcomes of AF ablation continue to increase as enor-
mous research efforts are focused on the mechanisms, out-
comes, and treatment of AF. For this reason, the HRS
initiated an effort to rewrite and update this Consensus
Statement. Reﬂecting both the worldwide importance of
AF, as well as the worldwide performance of AF ablation,
this document is the result of a joint partnership between
the HRS, EHRA, ECAS, the Asia Paciﬁc Heart Rhythm
Society (APHRS), and the Latin American Society of Car-
diac Stimulation and Electrophysiology (Sociedad Latin-
oamericana de Estimulación Cardíaca y Electroﬁsiología
[SOLAECE]). The purpose of this 2017 Consensus State-
ment is to provide a state-of-the-art review of the ﬁeld of
catheter and surgical ablation of AF and to report the ﬁnd-
ings of a writing group, convened by these ﬁve interna-
tional societies. The writing group is charged with
deﬁning the indications, techniques, and outcomes of AF
ablation procedures. Included within this document are
recommendations pertinent to the design of clinical trials
in the ﬁeld of AF ablation and the reporting of outcomes,
including deﬁnitions relevant to this topic.
The writing group is composed of 60 experts representing
11 organizations: HRS, EHRA, ECAS, APHRS, SOLAECE,
STS, ACC, American Heart Association (AHA), Canadian
Heart Rhythm Society (CHRS), Japanese Heart Rhythm So-
ciety (JHRS), and Brazilian Society of Cardiac Arrhythmiascumented by ECG monitoring or intracardiac electrogram monitoring
onds, or if less than 30 seconds, is present throughout the ECG
ubsequent episodes of AF requires that sinus rhythm be documented
es.
hould not be used to describe populations of AF patients undergoing
is sustained beyond 7 days but is less than 3 months in duration.
otentially confusing and should not be used to describe populations
lation.
as continuous AF of greater than 12 months’ duration.
inates spontaneously or with intervention within 7 days of onset.
of AF that is accepted by the patient and physician, and for which no
n sinus rhythm will be undertaken. The term permanent AF represents
he patient and physician rather than an inherent pathophysiological
F should not be used within the context of a rhythm control strategy
F ablation.
F that is sustained beyond 7 days.
diagnosed with an opportune ECG or rhythm strip.
Figure 1 Anatomical drawings of the heart relevant to AF ablation. This series of drawings shows the heart and associated relevant structures from four
different perspectives relevant to AF ablation. This drawing includes the phrenic nerves and the esophagus. A: The heart viewed from the anterior perspective.
B:The heart viewed from the right lateral perspective.C: The heart viewed from the left lateral perspective.D: The heart viewed from the posterior perspective.E:
The left atrium viewed from the posterior perspective. Illustration: Tim Phelps © 2017 Johns Hopkins University, AAM.
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All the members of the writing group, as well as peer re-
viewers of the document, have provided disclosure state-
ments for all relationships that might be perceived as real
or potential conﬂicts of interest. All author and peer reviewer
disclosure information is provided in Appendix A and
Appendix B.
In writing a consensus document, it is recognized that
consensus does not mean that there was complete agree-
ment among all the writing group members. Surveys of
the entire writing group were used to identify areas of
consensus concerning performance of AF ablation proced-
ures and to develop recommendations concerning the indi-
cations for catheter and surgical AF ablation. Theserecommendations were systematically balloted by the 60
writing group members and were approved by a minimum
of 80% of these members. The recommendations were
also subject to a 1-month public comment period. Each
partnering and collaborating organization then ofﬁcially re-
viewed, commented on, edited, and endorsed the ﬁnal docu-
ment and recommendations.
The grading system for indication of class of evidence
level was adapted based on that used by the ACC and the
AHA.3,4 It is important to state, however, that this
document is not a guideline. The indications for catheter
and surgical ablation of AF, as well as recommendations
for procedure performance, are presented with a Class and
Level of Evidence (LOE) to be consistent with what the
Figure 2 This ﬁgure includes six CT or MR images of the left atrium and pulmonary veins viewed from the posterior perspective. Common and uncommon
variations in PV anatomy are shown. A: Standard PV anatomy with 4 distinct PV ostia. B: Variant PV anatomy with a right common and a left common PV. C:
Variant PV anatomy with a left common PVwith a short trunk and an anomolous PV arising from the right posterior left atrial wall.D and E:Variant PV anatomy
with a common left PV with a long trunk. F: Variant PV anatomy with a massive left common PV.
Figure 3 Schematic drawing showing various hypotheses and proposals concerning the mechanisms of atrial ﬁbrillation. A: Multiple wavelets hypothesis. B:
Rapidly discharging automatic foci. C: Single reentrant circuit with ﬁbrillatory conduction. D: Functional reentry resulting from rotors or spiral waves. E: AF main-
tenance resulting from dissociation between epicardial and endocardial layers, with mutual interaction producing multiplying activity that maintains the arrhythmia.
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Figure 4 Structure and mechanisms of atrial ﬁbrillation. A: Schematic drawing of the left and right atria as viewed from the posterior perspective. The exten-
sion of muscular ﬁbers onto the PVs can be appreciated. Shown in yellow are the ﬁve major left atrial autonomic ganglionic plexi (GP) and axons (superior left GP,
inferior left GP, anterior right GP, inferior right GP, and ligament of Marshall). Shown in blue is the coronary sinus, which is enveloped by muscular ﬁbers that
have connections to the atria. Also shown in blue is the vein and ligament ofMarshall, which travels from the coronary sinus to the region between the left superior
PV and the left atrial appendage. B: The large and small reentrant wavelets that play a role in initiating and sustaining AF. C: The common locations of PV (red)
and also the common sites of origin of non-PV triggers (shown in green).D:Composite of the anatomic and arrhythmic mechanisms of AF. Adapted with permis-
sion from Calkins et al. Heart Rhythm 2012; 9:632–696.e21.2
e450 Heart Rhythm, Vol 14, No 10, October 2017reader is familiar with seeing in guideline statements. A Class
I recommendation means that the beneﬁts of the AF ablation
procedure markedly exceed the risks, and that AF ablation
should be performed; a Class IIa recommendation means
that the beneﬁts of an AF ablation procedure exceed the
risks, and that it is reasonable to perform AF ablation; a
Class IIb recommendation means that the beneﬁt of AF
ablation is greater or equal to the risks, and that AF
ablation may be considered; and a Class III
recommendation means that AF ablation is of no proven
beneﬁt and is not recommended.
The writing group reviewed and ranked evidence sup-
porting current recommendations with the weight of evi-
dence ranked as Level A if the data were derived from
high-quality evidence from more than one randomized clin-
ical trial, meta-analyses of high-quality randomized clinical
trials, or one or more randomized clinical trials corroboratedby high-quality registry studies. The writing group ranked
available evidence as Level B-R when there was
moderate-quality evidence from one or more randomized
clinical trials, or meta-analyses of moderate-quality random-
ized clinical trials. Level B-NR was used to denote
moderate-quality evidence from one or more well-
designed, well-executed nonrandomized studies, observa-
tional studies, or registry studies. This designation was
also used to denote moderate-quality evidence from meta-
analyses of such studies. Evidence was ranked as Level
C-LD when the primary source of the recommendation
was randomized or nonrandomized observational or registry
studies with limitations of design or execution, meta-
analyses of such studies, or physiological or mechanistic
studies of human subjects. Level C-EO was deﬁned as
expert opinion based on the clinical experience of the
writing group.
Figure 5 Schematic drawing showing mechanisms of atrial ﬂutter and atrial tachycardia. A: Isthmus-dependent reverse common (clockwise) atrial ﬂutter. B:
Isthmus-dependent common (counter clockwise) atrial ﬂutter. C: Focal atrial tachycardia with circumferential spread of activation of the atria (can arise from
multiple sites within the left and right atrium).D:Microreentrant atrial tachycardia with circumferential spread of activation of the atria.E: Perimitral atrial ﬂutter.
F: Roof-dependent atrial ﬂutter.
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several societies and professional organizations, and the at-
tempts of the group to reﬂect the current knowledge in the
ﬁeld adequately, this document is not intended as a guideline.
Rather, the group would like to refer to the current guidelines
on AF management for the purpose of guiding overall AF
management strategies.5,6 This consensus document is
speciﬁcally focused on catheter and surgical ablation of
AF, and summarizes the opinion of the writing group
members based on an extensive literature review as well as
their own experience. It is directed to all health care
professionals who are involved in the care of patients with
AF, particularly those who are caring for patients who are
undergoing, or are being considered for, catheter or
surgical ablation procedures for AF, and those involved in
research in the ﬁeld of AF ablation. This statement is not
intended to recommend or promote catheter or surgical
ablation of AF. Rather, the ultimate judgment regarding
care of a particular patient must be made by the health care
provider and the patient in light of all the circumstances
presented by that patient.
The main objective of this document is to improve pa-
tient care by providing a foundation of knowledge forthose involved with catheter ablation of AF. A second ma-
jor objective is to provide recommendations for designing
clinical trials and reporting outcomes of clinical trials of
AF ablation. It is recognized that this ﬁeld continues to
evolve rapidly. As this document was being prepared,
further clinical trials of catheter and surgical ablation of
AF were under way.Section 2: Deﬁnitions, Mechanisms, and
Rationale for AF Ablation
This section of the document provides deﬁnitions for use in
the diagnosis of AF. This section also provides an in-depth
review of the mechanisms of AF and rationale for catheter
and surgical AF ablation (Table 1, Figures 126).Section 3: Modiﬁable Risk Factors for AF and
Impact on Ablation
Management of patients with AF has traditionally consisted
of three main components: (1) anticoagulation for stroke pre-
vention; (2) rate control; and (3) rhythm control. With the
emergence of large amounts of data, which have both deﬁned
and called attention to the interaction between modiﬁable risk
Figure 6 Schematic of common lesion sets employed in AF ablation. A: The circumferential ablation lesions that are created in a circumferential fashion
around the right and the left PVs. The primary endpoint of this ablation strategy is the electrical isolation of the PV musculature. B: Some of the most
common sites of linear ablation lesions. These include a “roof line” connecting the lesions encircling the left and/or right PVs, a “mitral isthmus” line
connecting the mitral valve and the lesion encircling the left PVs at the end of the left inferior PV, and an anterior linear lesion connecting either the
“roof line” or the left or right circumferential lesion to the mitral annulus anteriorly. A linear lesion created at the cavotricuspid isthmus is also shown.
This lesion is generally placed in patients who have experienced cavotricuspid isthmus-dependent atrial ﬂutter clinically or have it induced during EP
testing. C: Similar to 6B, but also shows additional linear ablation lesions between the superior and inferior PVs resulting in a ﬁgure of eight lesion
sets as well as a posterior inferior line allowing for electrical isolation of the posterior left atrial wall. An encircling lesion of the superior vena cava
(SVC) directed at electrical isolation of the SVC is also shown. SVC isolation is performed if focal ﬁring from the SVC can be demonstrated. A subset
of operators empirically isolates the SVC. D: Representative sites for ablation when targeting rotational activity or CFAEs are targeted. Modiﬁed with
permission from Calkins et al. Heart Rhythm 2012; 9:632–696.e21.2
e452 Heart Rhythm, Vol 14, No 10, October 2017factors and the development of AF and outcomes of AF man-
agement, we believe it is time to include risk factor modiﬁca-
tion as the fourth pillar of AF management. This section of
the document reviews the link between modiﬁable risk fac-
tors and both the development of AF and their impacts on
the outcomes of AF ablation.
Section 4: Indications
Shown in Table 2, and summarized in Figures 7 and 8 of
this document, are the Consensus Indications for Catheter
and Surgical Ablation of AF. As outlined in the introduc-
tion section of this document, these indications are strati-
ﬁed as Class I, Class IIa, Class IIb, and Class IIIindications. The evidence supporting these indications is
provided, as well as a selection of the key references
supporting these levels of evidence. In making these rec-
ommendations, the writing group considered the body of
published literature that has deﬁned the safety and efﬁcacy
of catheter and surgical ablation of AF. Also considered in
these recommendations is the personal lifetime experience
in the ﬁeld of each of the writing group members. Both the
number of clinical trials and the quality of these trials were
considered. In considering the class of indications recom-
mended by this writing group, it is important to keep
several points in mind. First, these classes of indications
only deﬁne the indications for catheter and surgical
Table 2 Indications for catheter (A and B) and surgical (C, D, and E) ablation of atrial ﬁbrillation
Recommendation Class LOE References
Indications for catheter ablation of atrial ﬁbrillation
A. Indications for catheter ablation of atrial ﬁbrillation
Symptomatic AF
refractory or
intolerant to at
least one Class I or
III antiarrhythmic
medication
Paroxysmal: Catheter ablation is recommended. I A 7–18
Persistent: Catheter ablation is reasonable. IIa B-NR 8,16–26
Long-standing persistent: Catheter ablation
may be considered.
IIb C-LD 8,16–26
Symptomatic AF
prior to initiation
of antiarrhythmic
therapy with a
Class I or III
antiarrhythmic
medication
Paroxysmal: Catheter ablation is reasonable. IIa B-R 27–35
Persistent: Catheter ablation is reasonable. IIa C-EO
Long-standing persistent: Catheter ablation
may be considered.
IIb C-EO
B. Indications for catheter atrial ﬁbrillation ablation in populations of patients not well represented in clinical trials
Congestive heart
failure
It is reasonable to use similar indications for
AF ablation in selected patients with heart
failure as in patients without heart failure.
IIa B-R 36–52
Older patients
(.75 years of age)
It is reasonable to use similar indications for AF
ablation in selected older patients with AF as
in younger patients.
IIa B-NR 53–59
Hypertrophic
cardiomyopathy
It is reasonable to use similar indications for AF
ablation in selected patients with HCM as in
patients without HCM.
IIa B-NR 60–62
Young patients
(,45 years of age)
It is reasonable to use similar indications for AF
ablation in young patients with AF (,45
years of age) as in older patients.
IIa B-NR 63,64
Tachy-brady
syndrome
It is reasonable to offer AF ablation as an
alternative to pacemaker implantation in
patients with tachy-brady syndrome.
IIa B-NR 33–35
Athletes with AF It is reasonable to offer high-level athletes AF
as ﬁrst-line therapy due to the negative
effects of medications on athletic
performance.
IIa C-LD 27,28,65
Asymptomatic AF** Paroxysmal: Catheter ablation may be
considered in select patients.**
IIb C-EO 66,67
Persistent: Catheter ablation may be
considered in select patients.
IIb C-EO 68
(Continued )
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Table 2 (Continued )
Recommendation Class LOE References
Indications for surgical ablation of atrial ﬁbrillation
C. Indications for concomitant open (such as mitral valve) surgical ablation of atrial ﬁbrillation
Symptomatic AF
refractory or
intolerant to at
least one Class I or
III antiarrhythmic
medication
Paroxysmal: Surgical ablation is recommended. I B-NR 69–82
Persistent: Surgical ablation is recommended. I B-NR 69–82
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 69–82
Symptomatic AF prior
to initiation of
antiarrhythmic
therapy with a
Class I or III
antiarrhythmic
medication
Paroxysmal: Surgical ablation is recommended. I B-NR 69–82
Persistent: Surgical ablation is recommended. I B-NR 69–82
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 69–82
D. Indications for concomitant closed (such as CABG and AVR) surgical ablation of atrial ﬁbrillation
Symptomatic AF
refractory or
intolerant to at
least one Class I or
III antiarrhythmic
medication
Paroxysmal: Surgical ablation is recommended. I B-NR 83–88
Persistent: Surgical ablation is recommended. I B-NR 83–88
Long-standing persistent: Surgical ablation is
recommended.
I B-NR 83–88
Symptomatic AF prior
to initiation of
antiarrhythmic
therapy with a
Class I or III
antiarrhythmic
medication
Paroxysmal: Surgical ablation is reasonable. IIa B-NR 83–88
Persistent: Surgical ablation is reasonable. IIa B-NR 83–88
Long-standing persistent: Surgical ablation is
reasonable.
IIa B-NR 83–88
E. Indications for stand-alone and hybrid surgical ablation of atrial ﬁbrillation
Symptomatic AF
refractory or
intolerant to at
least one Class I or
III antiarrhythmic
medication
Paroxysmal: Stand-alone surgical ablation can
be considered for patients who have failed
one or more attempts at catheter ablation
and also for those who are intolerant or
refractory to antiarrhythmic drug therapy
and prefer a surgical approach, after review
of the relative safety and efﬁcacy of catheter
ablation versus a stand-alone surgical
approach.
IIb B-NR 83–85,89–103
Persistent: Stand-alone surgical ablation is
reasonable for patients who have failed one
or more attempts at catheter ablation and
also for those patients who prefer a surgical
approach after review of the relative safety
and efﬁcacy of catheter ablation versus a
stand-alone surgical approach.
IIa B-NR 83–85,89–103
Long-standing persistent: Stand-alone surgical
ablation is reasonable for patients who have
failed one or more attempts at catheter
ablation and also for those patients who
prefer a surgical approach after review of the
relative safety and efﬁcacy of catheter
ablation versus a stand-alone surgical
approach.
IIa B-NR 83–85,89–103
It might be reasonable to apply the indications
for stand-alone surgical ablation described
above to patients being considered for
hybrid surgical AF ablation.
IIb C-EO 103–108
AF 5 atrial ﬁbrillation; LOE 5 Level of Evidence; HCM 5 hypertrophic cardiomyopathy.
**A decision to perform AF ablation in an asymptomatic patient requires additional discussion with the patient because the potential beneﬁts of the procedure
for the patient without symptoms are uncertain.
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Figure 8 Indications for surgical ablation of atrial ﬁbrillation. Shown in this ﬁgur
standing persistent AF. The Class for each indication based on whether ablation is p
shown. The indications for surgical AF ablation are divided into whether the AF ab
(such as mitral valve replacement), a closed surgical procedure (such as coronary ar
performed solely for treatment of atrial ﬁbrillation.
Figure 7 Indications for catheter ablation of symptomatic atrial ﬁbrillation.
Shown in this ﬁgure are the indications for catheter ablation of symptomatic
paroxysmal, persistent, and long-standing persistent AF. The Class for each
indication based onwhether ablation is performed after failure of antiarrhythmic
drug therapy or as ﬁrst-line therapy is shown. Please refer to Table 2B and the
text for the indications for catheter ablation of asymptomatic AF.
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or a surgeon who has received appropriate training and/
or who has a certain level of experience and is performing
the procedure in an experienced center (Section 11). Cath-
eter and surgical ablation of AF are highly complex pro-
cedures, and a careful assessment of the beneﬁt and risk
must be considered for each patient. Second, these indica-
tions stratify patients based only on the type of AF and
whether the procedure is being performed prior to or
following a trial of one or more Class I or III antiar-
rhythmic medications. This document for the ﬁrst time
includes indications for catheter ablation of select asymp-
tomatic patients. As detailed in Section 9, there are many
other additional clinical and imaging-based variables that
can be used to further deﬁne the efﬁcacy and risk of abla-
tion in a given patient. Some of the variables that can be
used to deﬁne patients in whom a lower success rate or
a higher complication rate can be expected include the
presence of concomitant heart disease, obesity, sleep ap-
nea, left atrial (LA) size, patient age and frailty, as well
as the duration of time the patient has been in continuousSymptomatic 
AF
Paroxysmal 
AF
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Drugs
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e are the indications for surgical ablation of paroxysmal, persistent, and long-
erformed after failure of antiarrhythmic drug therapy or as ﬁrst-line therapy is
lation procedure is performed concomitantly with an open surgical procedure
tery bypass graft surgery), or as a stand-alone surgical AF ablation procedure
Table 3 Atrial ﬁbrillation ablation: strategies, techniques, and endpoints
Recommendation Class LOE References
PV isolation by catheter ablation Electrical isolation of the PVs is recommended during all
AF ablation procedures.
I A 7–16,19–26,109
Achievement of electrical isolation requires, at a
minimum, assessment and demonstration of entrance
block into the PV.
I B-R 7–16,19–26,109
Monitoring for PV reconnection for 20 minutes following
initial PV isolation is reasonable.
IIa B-R 9,110–120
Administration of adenosine 20 minutes following initial
PV isolation using RF energy with reablation if PV
reconnection might be considered.
IIb B-R 109,111–114,120–128
Use of a pace-capture (pacing along the ablation line)
ablation strategy may be considered.
IIb B-R 129–133
Demonstration of exit block may be considered. IIb B-NR 134–139
Ablation strategies to be considered
for use in conjunction with PV
isolation
If a patient has a history of typical atrial ﬂutter or typical
atrial ﬂutter is induced at the time of AF ablation,
delivery of a cavotricuspid isthmus linear lesion is
recommended.
I B-R 140–143
If linear ablation lesions are applied, operators should use
mapping and pacing maneuvers to assess for line
completeness.
I C-LD 19,141–149
If a reproducible focal trigger that initiates AF is
identiﬁed outside the PV ostia at the time of an AF
ablation procedure, ablation of the focal trigger should
be considered.
IIa C-LD 150–161
When performing AF ablation with a force-sensing RF
ablation catheter, a minimal targeted contact force of 5
to 10 grams is reasonable.
IIa C-LD 13,14,128,162–178
Posterior wall isolation might be considered for initial or
repeat ablation of persistent or long-standing
persistent AF.
IIb C-LD 21,179–185
Administration of high-dose isoproterenol to screen for
and then ablate non-PV triggers may be considered
during initial or repeat AF ablation procedures in
patients with paroxysmal, persistent, or long-standing
persistent AF.
IIb C-LD 150–161
DF-based ablation strategy is of unknown usefulness for
AF ablation.
IIb C-LD 186–193
The usefulness of creating linear ablation lesions in the
right or left atrium as an initial or repeat ablation
strategy for persistent or long-standing persistent AF is
not well established.
IIb B-NR 19,20,142,145–149,
194–201
The usefulness of linear ablation lesions in the absence of
macroreentrant atrial ﬂutter is not well established.
IIb C-LD 19,20,142,145–149,
194–201
The usefulness of mapping and ablation of areas of
abnormal myocardial tissue identiﬁed with voltage
mapping or MRI as an initial or repeat ablation strategy
for persistent or long-standing persistent AF is not well
established.
IIb B-R 179,202–211
The usefulness of ablation of complex fractionated atrial
electrograms as an initial or repeat ablation strategy
for persistent and long-standing persistent AF is not
well established.
IIb B-R 19,20,195–197,
212–220
The usefulness of ablation of rotational activity as an
initial or repeat ablation strategy for persistent and
long-standing persistent AF is not well established.
IIb B-NR 221–241
The usefulness of ablation of autonomic ganglia as an
initial or repeat ablation strategy for paroxysmal,
persistent, and long-standing persistent AF is not well
established.
IIb B-NR 19,89,242–259
Nonablation strategies to improve
outcomes
Weight loss can be useful for patients with AF, including
those who are being evaluated to undergo an AF
ablation procedure, as part of a comprehensive risk
factor management strategy.
IIa B-R 260–288
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Table 3 (Continued )
Recommendation Class LOE References
It is reasonable to consider a patient’s BMI when
discussing the risks, beneﬁts, and outcomes of AF
ablation with a patient being evaluated for an AF
ablation procedure.
IIa B-R 260–288
It is reasonable to screen for signs and symptoms of sleep
apnea when evaluating a patient for an AF ablation
procedure and to recommend a sleep evaluation if sleep
apnea is suspected.
IIa B-R 270,276–278,289–307
Treatment of sleep apnea can be useful for patients with
AF, including those who are being evaluated to
undergo an AF ablation procedure.
IIa B-R 270,276–278,289–307
The usefulness of discontinuation of antiarrhythmic drug
therapy prior to AF ablation in an effort to improve
long-term outcomes is unclear.
IIb C-LD 308–312
The usefulness of initiation or continuation of
antiarrhythmic drug therapy during the postablation
healing phase in an effort to improve long-term
outcomes is unclear.
IIb C-LD 308–312
Strategies to reduce the risks of
AF ablation
Careful identiﬁcation of the PV ostia is mandatory to
avoid ablation within the PVs.
I B-NR 313–335
It is recommended that RF power be reduced when
creating lesions along the posterior wall near the
esophagus.
I C-LD 68,336–365
It is reasonable to use an esophageal temperature probe
during AF ablation procedures to monitor esophageal
temperature and help guide energy delivery.
IIa C-EO 68,336,345,365
AF5 atrial ﬁbrillation; LOE5 Level of Evidence; PV5 pulmonary vein; RF5 radiofrequency; MRI5 magnetic resonance imaging; BMI5 body mass index.
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discussing the risks and beneﬁts of AF ablation with a
particular patient. In the presence of substantial risk or
anticipated difﬁculty of ablation, it could be
more appropriate to use additional antiarrhythmic drug
(AAD) options, even if the patient on face value mightFigure 9 Schematic drawing showing catheter ablation of atrial ﬁbrillation using
lesion set created using RF energy. Ablation lesions are delivered in a ﬁgure of eight
isthmus lesion created for ablation of typical atrial ﬂutter in a patient with a prior hist
at the time of ablation. A multielectrode circular mapping catheter is positioned in
system. Ablation lesions have been created surrounding the right PVs, and the cr
the lumen multielectrode circular mapping catheter is positioned in the left superiopresent with a Class I or IIa indication for ablation. Third,
it is important to consider patient preference and values.
Some patients are reluctant to consider a major procedure
or surgery and have a strong preference for a pharmacolog-
ical approach. In these patients, trials of antiarrhythmic
agents including amiodarone might be preferred to cathetereither RF energy or cryoballoon AF ablation. A: Shows a typical wide area
pattern around the left and right PV veins. Also shown is a linear cavotricuspid
ory of typical atrial ﬂutter or inducible isthmus-dependent typical atrial ﬂutter
the left inferior PV. B: Shows an ablation procedure using the cryoballoon
yoballoon ablation catheter is positioned in the left superior PV. A through
r PV. Illustration: Tim Phelps © 2017 Johns Hopkins University, AAM.
Table 4 Anticoagulation strategies: pre-, during, and postcatheter ablation of AF
Recommendation Class LOE References
Preablation For patients undergoing AF catheter ablation who have been therapeutically
anticoagulated with warfarin or dabigatran, performance of the ablation
procedure without interruption of warfarin or dabigatran is recommended.
I A 366–373
For patients undergoing AF catheter ablation who have been therapeutically
anticoagulated with rivaroxaban, performance of the ablation procedure
without interruption of rivaroxaban is recommended.
I B-R 374
For patients undergoing AF catheter ablation who have been therapeutically
anticoagulated with a NOAC other than dabigatran or rivaroxaban,
performance of the ablation procedure without withholding a NOAC dose is
reasonable.
IIa B-NR 375
Anticoagulation guidelines that pertain to cardioversion of AF should be
adhered to in patients who present for an AF catheter ablation procedure.
I B-NR 5,6
For patients anticoagulated with a NOAC prior to AF catheter ablation, it is
reasonable to hold one to two doses of the NOAC prior to AF ablation with
reinitiation postablation.
IIa B-NR 372,376–380
Performance of a TEE in patients who are in AF on presentation for AF catheter
ablation and who have been receiving anticoagulation therapeutically for
3 weeks or longer is reasonable.
IIa C-EO 5,6
Performance of a TEE in patients who present for ablation in sinus rhythm and
who have not been anticoagulated prior to catheter ablation is reasonable.
IIa C-EO 5,6
Use of intracardiac echocardiography to screen for atrial thrombi in patients
who cannot undergo TEE may be considered.
IIb C-EO 381–386
During ablation Heparin should be administered prior to or immediately following transseptal
puncture during AF catheter ablation procedures and adjusted to achieve
and maintain an ACT of at least 300 seconds.
I B-NR 369,380–382,387–393
Administration of protamine following AF catheter ablation to reverse heparin
is reasonable.
IIa B-NR 394
Postablation In patients who are not therapeutically anticoagulated prior to catheter
ablation of AF and in whom warfarin will be used for anticoagulation
postablation, low molecular weight heparin or intravenous heparin should
be used as a bridge for initiation of systemic anticoagulation with warfarin
following AF ablation.*
I C-EO
Systemic anticoagulation with warfarin* or a NOAC is recommended for at
least 2 months postcatheter ablation of AF.
I C-EO 1,2
Adherence to AF anticoagulation guidelines is recommended for patients who
have undergone an AF ablation procedure, regardless of the apparent
success or failure of the procedure.
I C-EO 5,6
Decisions regarding continuation of systemic anticoagulation more than
2 months post ablation should be based on the patient’s stroke risk proﬁle
and not on the perceived success or failure of the ablation procedure.
I C-EO 5,6
In patients who have not been anticoagulated prior to catheter ablation of AF
or in whom anticoagulation with a NOAC or warfarin has been interrupted
prior to ablation, administration of a NOAC 3 to 5 hours after achievement
of hemostasis is reasonable postablation.
IIa C-EO 372,376–380
Patients in whom discontinuation of anticoagulation is being considered
based on patient values and preferences should consider undergoing
continuous or frequent ECG monitoring to screen for AF recurrence.
IIb C-EO
AF5 atrial ﬁbrillation; LOE5 Level of Evidence; NOAC5 novel oral anticoagulant; TEE5 transesophageal electrocardiogram; ACT5 activated clotting time.
*Time in therapeutic range (TTR) should be . 65% – 70% on warfarin.
e458 Heart Rhythm, Vol 14, No 10, October 2017ablation. On the other hand, some patients prefer a non-
pharmacological approach. Fourth, it is important to recog-
nize that some patients early in the course of their AF
journey might have only infrequent episodes for many
years and/or could have AF that is responsive to well-
tolerated AAD therapy. And ﬁnally, it is important to
bear in mind that a decision to perform catheter or surgical
AF ablation should only be made after a patient carefully
considers the risks, beneﬁts, and alternatives to the
procedure.Section 5: Strategies, Techniques, and
Endpoints
The writing group recommendations for techniques to
be used for ablation of persistent and long-standing
persistent AF (Table 3), adjunctive ablation strategies,
nonablative strategies to improve outcomes of AF abla-
tion, and endpoints for ablation of paroxysmal, persis-
tent, and long-standing persistent AF are covered in
this section. A schematic overview of common lesion
Table 5 Signs and symptoms following AF ablation
Differential Suggested evaluation
Signs and symptoms of complications within a month postablation
Back pain Musculoskeletal, retroperitoneal hematoma Physical exam, CT imaging
Chest pain Pericarditis, pericardial effusion, coronary stenosis (ablation
related), pulmonary vein stenosis, musculoskeletal (after
cardioversion), worsening reﬂux
Physical exam, chest X-ray, ECG, echocardiogram, stress test,
cardiac catheterization, chest CT
Cough Infectious process, bronchial irritation (mechanical,
cryoballoon), pulmonary vein stenosis
Physical exam, chest X-ray, chest CT
Dysphagia Esophageal irritation (related to transesophageal
echocardiography), atrioesophageal ﬁstula
Physical exam, chest CT or MRI
Early satiety, nausea Gastric denervation Physical exam, gastric emptying study
Fever Infectious process, pericarditis, atrioesophageal ﬁstula Physical exam, chest X-ray, chest CT, urinalysis, laboratory
blood work
Fever, dysphagia,
neurological symptoms
Atrial esophageal ﬁstula Physical exam, laboratory blood work, chest CT or MRI; avoid
endoscopy with air insufﬂation
Groin pain at site of access Pseudoaneurysm, AV ﬁstula, hematoma Ultrasound of the groin, laboratory blood work; consider CT
scan if ultrasound negative
Headache Migraine (related to anesthesia or transseptal access,
hemorrhagic stroke), effect of general anesthetic
Physical exam, brain imaging (MRI)
Hypotension Pericardial effusion/tamponade, bleeding, sepsis, persistent
vagal reaction
Echocardiography, laboratory blood work
Hemoptysis PV stenosis or occlusion, pneumonia Chest X-ray, chest CT or MR scan, VQ scan
Neurological symptoms Cerebral embolic event, atrial esophageal ﬁstula Physical exam, brain imaging, chest CT or MRI
Shortness of breath Volume overload, pneumonia, pulmonary vein stenosis, phrenic
nerve injury
Physical exam, chest X-ray, chest CT, laboratory blood work
Signs and symptoms of complications more than a month postablation
Fever, dysphagia,
neurological symptoms
Atrial esophageal ﬁstula Physical exam, laboratory blood work, chest CT or MRI; avoid
endoscopy with air insufﬂation
Persistent cough, atypical
chest pain
Infectious process, pulmonary vein stenosis Physical exam, laboratory blood work, chest X-ray, chest CT or
MRI
Neurological symptoms Cerebral embolic event, atrial esophageal ﬁstula Physical exam, brain imaging, chest CT or MRI
Hemoptysis PV stenosis or occlusion, pneumonia CT scan, VQ scan
AF 5 atrial ﬁbrillation; ECG 5 electrocardiogram; CT 5 computed tomography; MRI 5 magnetic resonance imaging; VQ 5 ventilation-perfusion.
Table 6 Types of ambulatory cardiac monitoring devices
Type of recorder
Typical monitoring
duration
Continuous
recording
Event
recording
Auto
trigger Unique features
Holter monitor 24–48 hours,
approximately
7–30 days
Yes Yes N/A Short term, provides quantitative data on
arrhythmia burden
Patch monitor 1–3 weeks Yes Yes N/A Intermediate term, can provide continuous data
for up to several weeks; improved patient
compliance without lead wires
External loop recorder 1 month Yes Yes Variable Good correlation between symptoms and even brief
arrhythmias
External nonloop recorder Months No Yes No May be used long term and intermittently; will not
capture very brief episodes
Smartphone monitor Indeﬁnite No Yes No Provides inexpensive long-term intermittent
monitoring; dependent on patient compliance;
requires a smartphone
Mobile cardiac telemetry 30 days Yes Yes Yes Real time central monitoring and alarms; relatively
expensive
Implantable loop recorder Up to 3 years Yes Yes Yes Improved patient compliance for long-term use;
not able to detect 30-second episodes of AF due
to detection algorithm; presence of AF needs to
be conﬁrmed by EGM review because speciﬁcity
of detection algorithm is imperfect; expensive
Pacemakers or ICDs with
atrial leads
Indeﬁnite Yes Yes Yes Excellent AF documentation of burden and trends;
presence of AF needs to be conﬁrmed by
electrogram tracing review because speciﬁcity
of detection algorithms is imperfect; expensive
Wearable multisensor ECG
monitors
Indeﬁnite Yes Yes Yes ECG 3 leads, temp, heart rate, HRV, activity tracking,
respiratory rate, galvanic skin response
AF 5 atrial ﬁbrillation; ICD 5 implantable cardioverter deﬁbrillator; ECG 5 electrocardiogram; HRV 5 heart rate variability.
Calkins et al Catheter and Surgical Ablation of Atrial Fibrillation e459
Table 7 Selected clinical trials of catheter ablation of atrial ﬁbrillation and/or for FDA approval
Trial Year Type N AF type
Ablation
strategy
Initial time
frame
Effectiveness
endpoint Ablation success
Drug/
Control
success
P value for
success
Ablation
complications
Drug/Control
complications Comments
Clinical Trials Performed
for FDA Approval
JAMA 2010; 303:
333-340
(ThermoCool AF)14
2010 Randomized to RF
ablation or AAD,
multicenter
167 Paroxysmal PVI, optional
CFAEs and
lines
12 months Freedom from
symptomatic
paroxysmal atrial
ﬁbrillation, acute
procedural failure, or
changes in speciﬁed
drug regimen
66% 16% ,0.001 4.9% 8.8% FDA approval
received
JACC 2013; 61:
1713-1723
(STOP AF)9
2013 Randomized to
cryoballoon ablation
or AAD, multicenter
245 Paroxysmal PVI 12 months Freedom from any
detectable AF, use
of nonstudy AAD, or
nonprotocol
intervention for AF
70% 7% ,0.001 3.1% NA FDA approval
received
Heart Rhythm 2014;
11: 202-209
(TTOP)22
2014 Randomized to phased
RF ablation or AAD/
cardioversion,
multicenter
210 Persistent PVI 1 CFAEs 6 months Acute procedural
success, 90%
reduction in
AF burden, off AAD
56% 26% ,0.001 12.3% NA Not FDA
approved
JACC 2014; 64: 647-
656 (SMART-AF)13
2014 Nonrandomzied
multicenter study of
contact force-sensing
RF catheter,
comparing to
performance goals
172 Paroxysmal PVI, optional
CFAEs and
lines
12 months Freedom from
symptomatic AF,
ﬂutter, tachycardia,
acute procedural
failure, or changes in
AAD
72.5% N/A ,0.0001 7.5% NA FDA approval
received
Circulation 2015;
132: 907-915
(TOCCASTAR)12
2015 Randomized to contact
force sensing RF
catheter or approved
RF catheter,
multicenter
300 Paroxysaml PVI, optional
triggers,
CAFEs and
lines in both
arms
12 months Acute procedural success
1 Freedom from
Symptomatic AF/
Flutter/Tachycardia
off AAD
67.8% 69.4% 0.0073 for
noninferiority
7.2% 9.1% FDA approval
received
JACC 2015; 66:
1350-1360
(HeartLight)11
2015 Randomized to
laserballoon or
approved RF catheter,
multicenter
353 Paroxysmal PVI 6 CTI
ablation vs
PVI, optional
CFAEs, and
Lines
12 months Freedom from
Symptomatic AF/
Flutter/Tachycardia,
acute procedural
failure, AAD, or
non-prototocol
intervention
61.1% 61.7% 0.003 for
noninferiority
5.3% 6.4% FDA approval
received
First-Line Therapy Trials
JAMA 2005; 293:
2634-2640
(RAAFT)29
2005 Randomized to drug,
multicenter
70 Paroxysmal
(N567),
persistent
(N5 3)
PVI 12 months Freedom from
detectable AF
84% 37% ,0.01 9% 11%
NEJM 2012; 367:
1587-1595
(MANTRA-PAF)30
2012 Randomized to drug,
multicenter
294 Paroxysmal AF PVI, roof line,
optional
mitral and
tricuspid line
24 months Cumulative AF burden 13% AF
burden
19% AF
burden
NS 17% 15%
JAMA 2014; 311:
692-700
(RAAFT-2)31
2014 Randomized to drug
multicenter
127 Paroxysmal AF PVI plus optional
non-PVI
targets
24 months Freedom from
detectable AF,
ﬂutter, tachycardia
45% 28% 0.02 9% 4.9%
Other Paroxysmal AF
Ablation Trials
JACC 2006; 48:
2340-2347
(APAF)16
2006 Randomized to drug
single center
198 Paroxysmal AF PVI, mitral line
and tricuspid
line
12 months Freedom from
detectable AF, ﬂutter,
tachycardia
86% 22% ,0.001 1% 23%
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Circulation 2008; 118:
2498-2505 (A4)7
2008 Randomized to drug 112 Paroxysmal PVI (optional LA
lines, CTI, focal)
12 months Freedom from AF 89% 23% ,0.0001 5.7% 1.7%
NEJM 2016; 374:
2235-2245 (FIRE
AND ICE)10
2016 Randomized RF vs Cryo,
multicenter
762 Paroxysmal AF PVI 12 months Freedom from
detectable AF,
ﬂutter, tachycardia
64.1% (RF) 65.4%
(cryo)
NS 12.8% 10.2%
JACC 2016; 68:
2747-275715
2016 Randomized to hot
balloon or drug,
multicenter
100 Paroxysmal AF PVI 12 months Freedom from AF 59% 5% ,0.001 10.4% 4.7%
Other Persistent AF
Ablation Trials
NEJM 2006; 354:
934-94125
2006 Randomized to RF
ablation or to CV and
short term amio
146 Persistent PVI, roof,
mitral line
12 months No AF or ﬂutter
month 12
74% 58% 0.05 1.3% 1.4%
EHJ 2014; 35:
501-507 (SARA)26
2014 Randomized to drug
(2:1 ablation to drug),
multicenter
146 Persistent PVI (optional LA
lines, CFAEs)
12 months Freedom from AF/ﬂutter
lasting .24h
70% 44% 0.002 6.1% 4.20%
NEJM 2015; 372:
1812-182219
2015 Randomized ablation
strategies,
multicenter
589 Persistent PVI alone versus
PVI & CFAEs
or PVI & lines
18 months Freedom from aﬁb
with or without drugs
59% (PVI alone) 49% & 46% NS 6% 4.3% & 7.6%
Other Mixed Paroxysmal
and Persistent AF
Ablation Trials
J Med Assoc Thai
2003; 86 (Suppl 1):
S8-S1624
2003 Randomized to RF
ablation or
amiodarone
30 Paroxysmal (70%),
Persistent (30%)
PVI, mitral line,
CTI, SVC to
IVC
12 months Freedom from AF 79% 40% 0.018 6.70% 47%
EHJ 2006; 27:
216-22117
2006 Randomized to RF
ablation or drug,
multicenter
137 Paroxysmal (67%),
Persistent (33%)
PVI, mitral line,
CTI
12 months Freedom from AF,
ﬂutter, tachycardia
66% 9% ,0.001 4.40% 2.90%
JCVEP 2009, 20:
22-2818
2009 Randomized to RF
ablation or drug,
multicenter
70 Paroxysmal (41%),
Persistent (59%)
& type 2 DM
PVI, CTI,
optional
mitral line
and roof line
12 months Freedom from AF and
atypical atrial ﬂutter
80% 43% 0.001 2.90% 17%
Randomized Trials of AF
Ablation in Patients
with Heart Failure
NEJM 2008; 359:
1778-1785
(PABA-HF)38
2008 Randomized to RF
ablation of AVJ abl
and BiV pacing
81 Persistent (50%),
Paroxysmal
(50%), EF 27%
abl, 29% AVJ
PVI, optional
linear abl and
CFAEs
6 months Composite EF, 6 min
walk, MLWHF score;
freedom from AF
(secondary, mult proc,
1/- AA drugs)
88% AF free, EF
35% abl,
28% AVJ
(P,.001),.
QOL and 6 min
walk increase
with abl
,0.001 14.60% 17.50%
Heart 2011; 97:
740-74739
2011 Randomized to RF
ablation or
pharmacological rate
control
41 Persistent , EF 20%
abl, 16% rate
control
PVI, roof line,
CFAEs
6 months Change in LVEF, sinus
rhythm at 6 months
(secondary)
50% in NSR,
LVEF increase
4.5%
0% in NSR,
LVEF
increase
2.8%
0.6 (for EF
increase)
15% Not reported
JACC 2013; 61:
1894-190346
2013 Randomized to RF
ablation or
pharmacological rate
control
52 Persistent AF
(100%), EF 22%
abl, 25% rate
control
PVI, optional
linear abl
and CFAEs
12 months Change in peak O2
consumption (also
reported single
procedure off drug
ablation success)
Peak O2
consumption
increase
greater with
abl, 72% abl
success
0.018 15% Not reported
Circ A and E 2014;
7: 31-3840
2014 Randomized to RF
ablation or
pharmacological rate
control
50 Persistent AF
(100%), EF 32%
abl, 34% rate
control
PVI, optional
linear abl
and CFAEs
6 months Change in LVEF at 6
months, multiple
procedure freedom
from AF also reported
LVEF 40%with abl,
31% rate
control, 81%
AF freewith abl
0.015 7.70%
AF 5 atrial ﬁbrillation; RF 5 radiofrequency; AVJ 5 atrioventricular junction; abl 5 ablation; BiV 5 biventricular; EF 5 ejection fraction; PVI 5 pulmonary vein isolation; CFAEs 5 complex fractionated atrial
electrograms; MLWHF 5 Minnesota Living with Heart Failure; LVEF 5 left ventricular ejection fraction; QOL 5 quality of life; NSR 5 normal sinus rhythm.
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Table 8 Deﬁnitions of complications associated with AF ablation
Asymptomatic cerebral embolism Asymptomatic cerebral embolism is deﬁned as an occlusion of a blood vessel in the brain due to an
embolus that does not result in any acute clinical symptoms. Silent cerebral embolism is generally
detected using a diffusion weighted MRI.
Atrioesophageal ﬁstula An atrioesophageal ﬁstula is deﬁned as a connection between the atrium and the lumen of the esophagus.
Evidence supporting this diagnosis includes documentation of esophageal erosion combined with
evidence of a ﬁstulous connection to the atrium, such as air emboli, an embolic event, or direct
observation at the time of surgical repair. A CT scan or MRI scan is the most common method of
documentation of an atrioesophageal ﬁstula.
Bleeding Bleeding is deﬁned as a major complication of AF ablation if it requires and/or is treated with transfusion
or results in a 20% or greater fall in hematocrit.
Bleeding following cardiac surgery Excessive bleeding following a surgical AF ablation procedure is deﬁned as bleeding requiring reoperation
or 2 units of PRBC transfusion within any 24 hours of the ﬁrst 7 days following the index procedure.
Cardiac perforation We recommend that cardiac perforation be deﬁned together with cardiac tamponade. See “Cardiac
tamponade/perforation.”
Cardiac tamponade We recommend that cardiac tamponade be deﬁned together with cardiac perforation. See “Cardiac
tamponade/perforation.”
Cardiac tamponade/perforation Cardiac tamponade/perforation is deﬁned as the development of a signiﬁcant pericardial effusion during
or within 30 days of undergoing an AF ablation procedure. A signiﬁcant pericardial effusion is one that
results in hemodynamic compromise, requires elective or urgent pericardiocentesis, or results in a 1-cm
or more pericardial effusion as documented by echocardiography. Cardiac tamponade/perforation
should also be classiﬁed as “early” or “late” depending on whether it is diagnosed during or following
initial discharge from the hospital.
Deep sternal wound infection/
mediastinitis following
cardiac surgery
Deep sternal wound infection/mediastinitis following cardiac surgery requires one of the following: (1) an
organism isolated from culture of mediastinal tissue or ﬂuid; (2) evidence of mediastinitis observed
during surgery; (3) one of the following conditions: chest pain, sternal instability, or fever (.38C), in
combination with either purulent discharge from the mediastinum or an organism isolated from blood
culture or culture of mediastinal drainage.
Esophageal injury Esophageal injury is deﬁned as an erosion, ulceration, or perforation of the esophagus. The method of
screening for esophageal injury should be speciﬁed. Esophageal injury can be a mild complication
(erosion or ulceration) or a major complication (perforation).
Gastric motility/pyloric
spasm disorders
Gastric motility/pyloric spasm disorder should be considered a major complication of AF ablation when it
prolongs or requires hospitalization, requires intervention, or results in late disability, such as weight
loss, early satiety, diarrhea, or GI disturbance.
Major complication A major complication is a complication that results in permanent injury or death, requires intervention for
treatment, or prolongs or requires hospitalization for more than 48 hours. Because early recurrences of
AF/AFL/AT are to be expected following AF ablation, recurrent AF/AFL/AT within 3 months that requires
or prolongs a patient’s hospitalization should not be considered to be a major complication of AF
ablation.
Mediastinitis Mediastinitis is deﬁned as inﬂammation of the mediastinum. Diagnosis requires one of the following: (1)
an organism isolated from culture of mediastinal tissue or ﬂuid; (2) evidence of mediastinitis observed
during surgery; (3) one of the following conditions: chest pain, sternal instability, or fever (.38C), in
combination with either purulent discharge from the mediastinum or an organism isolated from blood
culture or culture of mediastinal drainage.
Myocardial infarction in the
context of AF ablation
The universal deﬁnition of myocardial infarction395 cannot be applied in the context of catheter or
surgical AF ablation procedures because it relies heavily on cardiac biomarkers (troponin and CPK),
which are anticipated to increase in all patients who undergo AF ablation as a result of the ablation of
myocardial tissue. Similarly, chest pain and other cardiac symptoms are difﬁcult to interpret in the
context of AF ablation both because of the required sedation and anesthesia and also because most
patients experience chest pain following the procedure as a result of the associated pericarditis that
occurs following catheter ablation. We therefore propose that a myocardial infarction, in the context of
catheter or surgical ablation, be deﬁned as the presence of any one of the following criteria: (1)
detection of ECG changes indicative of new ischemia (new ST-T wave changes or new LBBB) that persist
for more than 1 hour; (2) development of new pathological Q waves on an ECG; (3) imaging evidence of
new loss of viable myocardium or new regional wall motion abnormality.
Pericarditis Pericarditis should be considered a major complication following ablation if it results in an effusion that
leads to hemodynamic compromise or requires pericardiocentesis, prolongs hospitalization by more
than 48 hours, requires hospitalization, or persists for more than 30 days following the ablation
procedure.
Phrenic nerve paralysis Phrenic nerve paralysis is deﬁned as absent phrenic nerve function as assessed by a sniff test. A phrenic
nerve paralysis is considered to be permanent when it is documented to be present 12 months or longer
following ablation.
Pulmonary vein stenosis Pulmonary vein stenosis is deﬁned as a reduction of the diameter of a PV or PV branch. PV stenosis can be
categorized as mild,50%, moderate 50%–70%, and severe70% reduction in the diameter of the PV
or PV branch. A severe PV stenosis should be considered a major complication of AF ablation.
Serious adverse device effect A serious adverse device effect is deﬁned as a serious adverse event that is attributed to use of a particular
device.
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Stiff left atrial syndrome Stiff left atrial syndrome is a clinical syndrome deﬁned by the presence of signs of right heart failure in the
presence of preserved LV function, pulmonary hypertension (mean PA pressure .25 mm Hg or during
exercise.30 mm Hg), and large V waves10 mm Hg or higher) on PCWP or left atrial pressure tracings
in the absence of signiﬁcant mitral valve disease or PV stenosis.
Stroke or TIA postablation Stroke diagnostic criteria
 Rapid onset of a focal or global neurological deﬁcit with at least one of the following: change in level
of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body,
dysphasia or aphasia, hemianopia, amaurosis fugax, or other neurological signs or symptoms
consistent with stroke
 Duration of a focal or global neurological deﬁcit 24 hours; OR ,24 hours if therapeutic
intervention(s) were performed (e.g., thrombolytic therapy or intracranial angioplasty); OR available
neuroimaging documents a new hemorrhage or infarct; OR the neurological deﬁcit results in death.
 No other readily identiﬁable nonstroke cause for the clinical presentation (e.g., brain tumor, trauma,
infection, hypoglycemia, peripheral lesion, pharmacological inﬂuences).*
 Conﬁrmation of the diagnosis by at least one of the following: neurology or neurosurgical specialist;
neuroimaging procedure (MRI or CT scan or cerebral angiography); lumbar puncture (i.e., spinal ﬂuid
analysis diagnostic of intracranial hemorrhage)
Stroke deﬁnitions
 Transient ischemic attack: new focal neurological deﬁcit with rapid symptom resolution (usually 1 to 2
hours), always within 24 hours; neuroimaging without tissue injury
 Stroke: (diagnosis as above, preferably with positive neuroimaging study);
Minor—Modiﬁed Rankin score ,2 at 30 and 90 days†
Major—Modiﬁed Rankin score 2 at 30 and 90 days
Unanticipated adverse device
effect
Unanticipated adverse device effect is deﬁned as complication of an ablation procedure that has not been
previously known to be associated with catheter or surgical ablation procedures.
Vagal nerve injury Vagal nerve injury is deﬁned as injury to the vagal nerve that results in esophageal dysmotility or
gastroparesis. Vagal nerve injury is considered to be a major complication if it prolongs hospitalization,
requires hospitalization, or results in ongoing symptoms for more than 30 days following an ablation
procedure.
Vascular access complication Vascular access complications include development of a hematoma, an AV ﬁstula, or a pseudoaneurysm. A
major vascular complication is deﬁned as one that requires intervention, such as surgical repair or
transfusion, prolongs the hospital stay, or requires hospital admission.
AF 5 atrial ﬁbrillation; CT 5 computed tomography; MRI 5 magnetic resonance imaging; PRBC 5 packed red blood cell; AFL 5 atrial ﬂutter; AT 5 atrial
tachycardia; CPK 5 creatine phosphokinase; ECG 5 electrocardiogram; LBBB 5 left bundle branch block.
*Patients with nonfocal global encephalopathy will not be reported as a stroke without unequivocal evidence based on neuroimaging studies.
†Modiﬁed Rankin score assessments should be made by qualiﬁed individuals according to a certiﬁcation process. If there is discordance between the 30- and
90-day modiﬁed Rankin scores, a ﬁnal determination of major versus minor stroke will be adjudicated by the neurology members of the clinical events committee.
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Figure 6.Section 6: Technology and Tools
This section of the consensus statement provides an update
on many of the technologies and tools that are employed
for AF ablation procedures. It is important to recognize
that this is not a comprehensive listing and that new tech-
nologies, tools, and approaches are being developed. It is
also important to recognize that radiofrequency (RF) en-
ergy is the dominant energy source available for ablation
of typical and atypical atrial ﬂutter (AFL). Although cryoa-
blation is a commonly employed tool for AF ablation, it is
not well suited for ablation of typical or atypical AFL.
Other energy sources and tools are available in some parts
of the world and/or are in various stages of development
and/or clinical investigation. Shown in Figure 9 are sche-
matic drawings of AF ablation using point-by-point RF
energy (Figure 9A) and AF ablation using the cryoballoon
(CB) system (Figure 9B).Section 7: Technical Aspects of Ablation to
Maximize Safety and Anticoagulation
Anticoagulation strategies pre-, during, and postcatheter
ablation of AF (Table 4); signs and symptoms of complica-
tions that can occur within the ﬁrst several months following
ablation (Table 5); anesthesia or sedation during ablation;
and approaches to minimize risk of an atrial esophageal ﬁs-
tula are discussed in this section.Section 8: Follow-up Considerations
AF ablation is an invasive procedure that entails risks,
most of which are present during the acute procedural
period. However, complications can also occur in the
weeks or months following ablation. Recognizing com-
mon symptoms after AF ablation and distinguishing
those that require urgent evaluation and referral to an
electrophysiologist is an important part of follow-up
after AF ablation. The success of AF ablation is based
in large part on freedom from AF recurrence based
on ECG monitoring. Arrhythmia monitoring can be
Table 9 Incidence, prevention, diagnosis, and treatment of selected complications of AF ablation
Complication Incidence Selected prevention techniques Diagnostic testing Selected treatment options References
Air embolism ,1% Sheath management Nothing or cardiac catheterization Supportive care with ﬂuid, oxygen,
head down tilt, hyperbaric oxygen
388,396–401
Asymptomatic cerebral
emboli (ACE)
2% to 15% Anticoagulation, catheter and sheath
management, TEE
Brain MRI None 402–419
Atrial esophageal ﬁstula 0.02% to 0.11% Reduce power, force, and RF time on
posterior wall, monitor esophageal temp,
use proton pump inhibitors; avoid energy
delivery over esophagus
CT scan of chest, MRI; avoid
endoscopy with air insufﬂation
Surgical repair 337–365,420–456
Cardiac tamponade 0.2% to 5% Cather manipulation, transseptal technique,
reduce power, force, and RF time
Echocardiography Pericardiocentesis or surgical
drainage
338,343,347,457–467
Coronary artery stenosis/
occlusion
,0.1% Avoid high-power energy delivery near
coronary arteries
Cardiac catheterization PTCA 468–476
Death ,0.1% to 0.4% Meticulous performance of procedure,
attentive postprocedure care
NA NA 338,343,347,458,477
Gastric hypomotility 0% to 17% Reduce power, force, and RF time on
posterior wall
Endoscopy, barium swallow, gastric
emptying study
Metoclopramide, possibly
intravenous erythromycin
478–490
Mitral valve entrapment ,0.1% Avoid circular catheter placement near or
across mitral valve; clockwise torque on
catheter
Echocardiography Gentle catheter manipulation,
surgical extraction
491–498
Pericarditis 0% to 50% None proven Clinical history, ECG, sedimentation
rate, echocardiogram
NSAID, colchicine, steroids 499–506
Permanent phrenic nerve
paralysis
0% to 0.4% Monitor diaphragm during phrenic pacing,
CMAP monitoring, phrenic pacing to
identify location and adjust lesion
location
CXR, sniff test Supportive care 9,11,156,347,367,446,
457,478,479,487–490,
507–528
Pulmonary vein stenosis ,1% Avoid energy delivery within PV CT or MRI, V/Q wave scan Angioplasty, stent, surgery 9,11,313,316–335,457,
529–531
Radiation injury ,0.1% Minimize ﬂuoroscopy exposure, especially
in obese and repeat ablation patients,
X-ray equipment
None Supportive care, rarely skin graft 513,532–550
Stiff left atrial syndrome ,1.5% Limit extent of left atrial ablation Echocardiography, cardiac
catheterization
Diuretics 551–558
Stroke and TIA 0% to 2% Pre-, post-, and intraprocedure
anticoagulation, catheter and sheath
management, TEE
Head CT or MRI, cerebral angiography Thrombolytic therapy, angioplasty 10–13,338,347,367,458,
559–565
Vascular complications 0.2% to 1.5% Vascular access techniques, ultrasound-
guided access, anticoagulation
management
Vascular ultrasound, CT scan Conservative treatment, surgical
repair, transfusion
338,347,371,373,374,
380,458,511,566–575
AF5 atrial ﬁbrillation; CT5 computed tomography; MRI5magnetic resonance imaging; TEE5 transesophageal electrocardiogram; RF5 radiofrequency; PTCA5 percutaneous transluminal coronary angioplasty;
NA 5 not applicable; ECG 5 electrocardiogram; NSAID 5 nonsteroidal anti-inﬂammatory drug; CMAP 5 compound motor action potentials; CXR 5 chest X-ray; TIA 5 transient ischemic attack.
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Table 10 Deﬁnitions for use when reporting outcomes of AF ablation and in designing clinical trials of catheter or surgical ablation of AF
Acute procedural success
(pulmonary vein isolation)
Acute procedural success is deﬁned as electrical isolation of all pulmonary veins. A minimal assessment of
electrical isolation of the PVs should consist of an assessment of entrance block. If other methods are
used to assess PVI, including exit block and/or the use of provocative agents such as adenosine or
isoproterenol, they should be prespeciﬁed. Furthermore, it is recommended that the wait time used to
screen for early recurrence of PV conduction once initial electrical isolation is documented be speciﬁed
in all prospective clinical trials.
Acute procedural success (not
related by pulmonary vein
isolation)
Typically, this would apply to substrate ablation performed in addition to PVI for persistent AF. Although
some have proposed AF termination as a surrogate for acute procedural success, its relationship to
long-term success is controversial. Complete elimination of the additional substrate (localized
rotational activation, scar region, non-PV trigger, or other target) and/or demonstration of
bidirectional conduction block across a linear ablation lesion would typically be considered the
appropriate endpoint.
One-year success* One-year success is deﬁned as freedom from AF/AFL/AT after removal from antiarrhythmic drug therapy as
assessed from the end of the 3month blanking period to 12 months following the ablation procedure.
Because cavotricuspid isthmus-dependent atrial ﬂutter is easily treated with cavotricuspid isthmus
ablation and is not an iatrogenic arrhythmia following a left atrial ablation procedure for AF, it is
reasonable for clinical trials to choose to prespecify that occurrence of isthmus-dependent atrial
ﬂutter, if conﬁrmed by entrainment maneuvers during electrophysiology testing, should not be
considered an ablation failure or primary effectiveness endpoint.
Alternative one-year success Although the one-year success deﬁnition provided above remains the recommended end point that
should be reported in all AF ablation trials, and the endpoint for which the objective performance
criteria listed below were developed, the Task Force recognizes that alternative deﬁnitions for success
can be used if the main goal of therapy in the study is to relieve AF-related symptoms and to improve
patient QOL. In particular, it is appropriate for clinical trials to deﬁne success as freedom from only
symptomatic AF/AFL/AT after removal from antiarrhythmic drug therapy as assessed from the end of
the 3-month blanking period to 12 months following the ablation procedure if the main goal of therapy
in the study is to relieve AF-related symptoms and to improve patient QOL. However, because symptoms
of AF can resolve over time, and because studies have shown that asymptomatic AF represents a greater
proportion of all AF postablation than prior to ablation, clinical trials need to continue to report
freedom from both symptomatic and asymptomatic AF even if this alternative one year success
deﬁnition is used as the primary trial endpoint.
Clinical/partial success* It is reasonable for clinical trials to deﬁne and incorporate one or more secondary deﬁnitions of success
that can be referred to as “clinical success” or “partial success.” If these alternative deﬁnitions of
success are included, they should be deﬁned prospectively. In prior Consensus Documents the Task
Force has proposed that clinical/partial success be deﬁned as a “75% or greater reduction in the
number of AF episodes, the duration of AF episodes, or the % time a patient is in AF as assessed with a
device capable of measuring AF burden in the presence or absence of previously ineffective
antiarrhythmic drug therapy.” Because there is no ﬁrm scientiﬁc basis for selecting the cutoff of 75%
rather than a different cutoff, this prior recommendation is provided only as an example of what future
clinical trials may choose to use as a deﬁnition of clinical/partial success.
Long-term success* Long-term success is deﬁned as freedom from AF/AFL/AT recurrences following the 3-month blanking
period through a minimum of 36-month follow-up from the date of the ablation procedure in the
absence of Class I and III antiarrhythmic drug therapy.
Recurrent AF/AFL/AT Recurrent AF/AFL/AT is deﬁned as AF/AFL/AT of at least 30 seconds’ duration that is documented by an
ECG or device recording system and occurs following catheter ablation. Recurrent AF/AFL/AT may occur
within or following the post ablation blanking period. Recurrent AF/AFL/AT that occurs within the
postablation blanking period is not considered a failure of AF ablation.
Early recurrence of AF/AFL/AT Early recurrence of AF/AFL/AT is deﬁned as a recurrence of atrial ﬁbrillation within three months of
ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed as a “recurrence.” These
are not counted toward the success rate if a blanking period is speciﬁed.
Recurrence of AF/AFL/AT Recurrence of AF/AFL/AT postablation is deﬁned as a recurrence of atrial ﬁbrillation more than 3 months
following AF ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed as a
“recurrence.”
Late recurrence of AF/AFL/AT Late recurrence of AF/AFL/AT is deﬁned as a recurrence of atrial ﬁbrillation 12 months or more after AF
ablation. Episodes of atrial tachycardia or atrial ﬂutter should also be classiﬁed as a “recurrence.”
Blanking period A blanking period of three months should be employed after ablation when reporting efﬁcacy outcomes.
Thus, early recurrences of AF/AFL/AT within the ﬁrst 3 months should not be classiﬁed as treatment
failure. If a blanking period of less than 3 months is chosen, it should be prespeciﬁed and included in
the Methods section.
Stroke screening A risk-based approach to determine the level of postablation stroke screening in clinical trials is
recommended by the Task Force. For ablation devices with a lower risk of stroke and for which a stroke
signal has not been reported, a minimum standardized neurological assessment of stroke should be
conducted by a physician at baseline and at hospital discharge or 24 hours after the procedure,
whichever is later. If this neurological assessment demonstrates new abnormal ﬁndings, the patient
should have a formal neurological consult and examination with appropriate imaging (i.e., DW-MRI),
(Continued )
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used to conﬁrm any suspected diagnosis of stroke. For devices in which a higher risk of stroke is
suspected or revealed in prior trials, a formal neurological examination by a neurologist at discharge or
24 hours after the procedure, whichever is later, is recommended. Appropriate imaging should be
obtained if this evaluation reveals a new neurological ﬁnding. In some studies in which delayed stroke
is a concern, repeat neurological screening at 30 days postablation might be appropriate.
Detectable AF/AFL/AT Detectable AF is deﬁned as AF/AFL/AT of at least 30 seconds’ duration when assessed with ECG
monitoring. If other monitoring systems are used, including implantable pacemakers, implantable
deﬁbrillators, and subcutaneous ECG monitoring devices, the deﬁnition of detectable AF needs to be
prespeciﬁed in the clinical trial based on the sensitivity and speciﬁcity of AF detection with the
particular device. We recommend that episodes of atrial ﬂutter and atrial tachycardia be included
within the broader deﬁnition of a detectable AF/AFL/AT episode.
AF/AFL/AT burden It is reasonable for clinical trials to incorporate AF/AFL/AT burden as a secondary endpoint in a clinical
trial of AF ablation. In stating this it is recognized that there are no conclusive data that have validated
a rate of AF burden reduction as a predictor of patient beneﬁt (i.e. reduction in mortality and major
morbidities such as stroke, CHF, QOL, or hospitalization). If AF burden is included, it is important to
predeﬁne and standardize the monitoring technique that will be used to measure AF burden. Available
monitoring techniques have been discussed in this document. Should AF burden be selected as an
endpoint in a clinical trial, the chosen monitoring technique should be employed at least a month prior
to ablation to establish a baseline burden of AF.
Entrance block Entrance block is deﬁned as the absence, or if present, the dissociation, of electrical activity within the PV
antrum. Entrance block is most commonly evaluated using a circular multielectrode mapping catheter
positioned at the PV antrum. Entrance block can also be assessed using detailed point-by-point
mapping of the PV antrum guided by an electroanatomical mapping system. The particular method used
to assess entrance block should be speciﬁed in all clinical trials. Entrance block of the left PVs should be
assessed during distal coronary sinus or left atrial appendage pacing in order to distinguish far-ﬁeld
atrial potentials from PV potentials. It is recommended that reassessment of entrance block be
performed a minimum of 20 minutes after initial establishment of PV isolation.
Procedural endpoints for AF
ablation strategies not
targeting the PVs
Procedural endpoints for AF ablation strategies not targeting the PVs: The acute procedural endpoints for
ablation strategies not targeting the PVs vary depending on the speciﬁc ablation strategy and tool. It is
important that they be prespeciﬁed in all clinical trials. For example, if a linear ablation strategy is
used, documentation of bidirectional block across the ablation line must be shown. For ablation of
CFAEs, rotational activity, or non-PV triggers, the acute endpoint should at a minimum be elimination
of CFAEs, rotational activity, or non-PV triggers. Demonstration of AF slowing or termination is an
appropriate procedural endpoint, but it is not required as a procedural endpoint for AF ablation
strategies not targeting the PVs.
Esophageal temperature
monitoring
Esophageal temperature monitoring should be performed in all clinical trials of AF ablation. At a
minimum, a single thermocouple should be used. The location of the probe should be adjusted during
the procedure to reﬂect the location of energy delivery. Although this document does not provide
formal recommendations regarding the speciﬁc temperature or temperature change at which energy
delivery should be terminated, the Task Force does recommend that all trials prespecify temperature
guidelines for termination of energy delivery.
Enrolled subject An enrolled subject is deﬁned as a subject who has signed written informed consent to participate in the
trial in question.
Exit block Exit block is deﬁned as the inability to capture the atrium during pacing at multiple sites within the PV
antrum. Local capture of musculature within the pulmonary veins and/or antrum must be documented
to be present to make this assessment. Exit block is demonstrated by a dissociated spontaneous
pulmonary vein rhythm.
Nonablative strategies The optimal nonablative therapy for patients with persistent and long-standing persistent AF who are
randomized to the control arm of an AF ablation trial is a trial of a new Class I or III antiarrhythmic
agent or a higher dose of a previously failed antiarrhythmic agent. For patients with persistent or long-
standing persistent AF, performance of a direct-current cardioversion while taking the new or dose
adjusted antiarrhythmic agent should be performed, if restoration of sinus rhythm is not achieved
following initiation and/or dose adjustment of antiarrhythmic drug therapy. Failure of pharmacological
cardioversion alone is not adequate to declare this pharmacological strategy unsuccessful.
Noninducibility of atrial
ﬁbrillation
Noninducibility of atrial ﬁbrillation is deﬁned as the inability to induce atrial ﬁbrillation with a
standardized prespeciﬁed pharmacological or electrical stimulation protocol. The stimulation protocol
should be prespeciﬁed in the speciﬁc clinical trial. Common stimulation approaches include a high-
dose isoproterenol infusion protocol or repeated atrial burst pacing at progressively more rapid rates.
Patient populations for inclusion
in clinical trials
It is considered optimal for clinical trials to enroll patients with only one type of AF: paroxysmal,
persistent, or long-standing persistent. If more than one type of AF patient is enrolled, the results of
the trial should also be reported separately for each of the AF types. It is recognized that “early
persistent” AF responds to AF ablation to a similar degree as patients with paroxysmal AF and that the
response of patients with “late persistent AF” is more similar to that in those with long-standing
persistent AF.
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Therapy consolidation period Following a 3-month blanking period, it is reasonable for clinical trials to incorporate an additional 1- to
3-month therapy consolidation period. During this time, adjustment of antiarrhythmic medications
and/or cardioversion can be performed. Should a consolidation period be incorporated into a clinical
trial design, the minimum follow-up duration should be 9 months following the therapy consolidation
period. Performance of a repeat ablation procedure during the blanking or therapy consolidation period
would “reset” the endpoint of the study and trigger a new 3-month blanking period. Incorporation of a
therapy consolidation period can be especially appropriate for clinical trials evaluating the efﬁcacy of
AF ablation for persistent or long-standing persistent AF. The challenge of this approach is that it
prolongs the overall study duration. Because of this concern regarding overall study duration, we
suggest that the therapy consolidation period be no more than 3 months in duration following the 3-
month blanking period.
Recommendations regarding
repeat ablation procedures
It is recommended that all clinical trials report the single procedure efﬁcacy of catheter ablation. Success
is deﬁned as freedom from symptomatic or asymptomatic AF/AFL/AT of 30 seconds or longer at 12
months postablation. Recurrences of AF/AFL/AT during the ﬁrst 3-month blanking period post-AF
ablation are not considered a failure. Performance of a repeat ablation procedure at any point after the
initial ablation procedure should be considered a failure of a single procedure strategy. It is acceptable
for a clinical trial to choose to prespecify and use a multiprocedure success rate as the primary endpoint
of a clinical trial. When a multiprocedure success is selected as the primary endpoint, efﬁcacy should be
deﬁned as freedom from AF/ﬂutter or tachycardia at 12 months after the ﬁnal ablation procedure. In
the case of multiple procedures, repeat ablation procedures can be performed at any time following the
initial ablation procedure. All ablation procedures are subject to a 3-month post blanking window, and
all ablation trials should report efﬁcacy at 12 months after the ﬁnal ablation procedure.
Cardioversion deﬁnitions
Failed electrical cardioversion Failed electrical cardioversion is deﬁned as the inability to restore sinus rhythm for 30 seconds or longer
following electrical cardioversion.
Successful electrical
cardioversion
Successful electrical cardioversion is deﬁned as the ability to restore sinus rhythm for at least 30 seconds
following cardioversion.
Immediate AF recurrence
postcardioversion
Immediate AF recurrence postcardioversion is deﬁned as a recurrence of AF within 24 hours following
cardioversion. The most common time for an immediate recurrence is within 30–60 minutes
postcardioversion.
Early AF recurrence
postcardioversion
Early AF recurrence postcardioversion is deﬁned as a recurrence of AF within 30 days of a successful
cardioversion.
Late AF recurrence
postcardioversion
Late AF recurrence postcardioversion is deﬁned as recurrence of AF more than 30 days following a
successful cardioversion.
Surgical ablation deﬁnitions
Hybrid AF surgical ablation
procedure
Hybrid AF surgical ablation procedure is deﬁned as a joint AF ablation procedure performed by
electrophysiologists and cardiac surgeons either as part of a single “joint” procedure or performed as
two preplanned separate ablation procedures separated by no more than 6 months.
Surgical Maze ablation
procedure
Surgical Maze ablation procedure is deﬁned as a surgical ablation procedure for AF that includes, at a
minimum, the following components: (1) line from SVC to IVC; (2) line from IVC to the tricuspid valve;
(3) isolation of the PVs; (4) isolation of the posterior left atrium; (5) line from MV to the PVs; (6)
management of the LA appendage.
Stand-alone surgical AF
ablation
A surgical AF ablation procedure during which other cardiac surgical procedures are not performed such as
CABG, valve replacement, or valve repair.
Nomenclature for types of
surgical AF ablation
procedures
We recommend that the term “Maze” procedure is appropriately used only to refer to the biatrial lesion set
of the Cox-Maze operation. It requires ablation of the RA and LA isthmuses. Less extensive lesion sets
should not be referred to as a “Maze” procedure, but rather as a surgical AF ablation procedure. In
general, surgical ablation procedures for AF can be grouped into three different groups: (1) a full
biatrial Cox-Maze procedure; (2) PVI alone; and (3) PVI combined with left atrial lesion sets.
Hybrid epicardial and
endocardial AF ablation
This term refers to a combined AF ablation procedure involving an off-pumpminimally invasive surgical AF
ablation as well as a catheter-based AF ablation procedure designed to complement the surgical lesion
set. Hybrid ablation procedures may be performed in a single-procedure setting in a hybrid operating
room or a cardiac catheterization laboratory environment, or it can be staged. When staged, it is most
typical to have the patient undergo the minimally invasive surgical ablation procedure ﬁrst following
by a catheter ablation procedure 1 to 3 months later. This latter approach is referred to as a “staged
Hybrid AF ablation procedure.”
Minimum AF documentation, endpoints, TEE performance, and success rates in clinical trials
Minimum documentation for
paroxysmal AF
The minimum AF documentation requirement for paroxysmal AF is (1) physician’s note indicating
recurrent self-terminating AF and (2) one electrocardiographically documented AF episode within 6
months prior to the ablation procedure.
Minimum documentation for
persistent AF
The minimum AF documentation requirement for persistent AF is (1) physician’s note indicating
continuous AF.7 days but no more than 1 year and (2) a 24-hour Holter within 90 days of the ablation
procedure showing continuous AF.
(Continued )
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Table 10 (Continued )
Minimum documentation for
early persistent AF
The minimum AF documentation requirement for persistent AF is (1) physician’s note indicating
continuous AF .7 days but no more than 3 months and (2) a 24-hour Holter showing continuous AF
within 90 days of the ablation procedure.
Minimum documentation for
long-standing persistent AF
The minimum AF documentation requirement for long-standing persistent AF is as follows: physician’s
note indicating at least 1 year of continuous AF plus a 24-hour Holter within 90 days of the ablation
procedure showing continuous AF. The performance of a successful cardioversion (sinus rhythm .30
seconds) within 12 months of an ablation procedure with documented early recurrence of AF within 30
days should not alter the classiﬁcation of AF as long-standing persistent.
Symptomatic AF/AFL/AT AF/AFL/AT that results in symptoms that are experienced by the patient. These symptoms can include but
are not limited to palpitations, presyncope, syncope, fatigue, and shortness of breath. For patients in
continuous AF, reassessment of symptoms after restoration of sinus rhythm is recommended to
establish the relationship between symptoms and AF.
Documentation of
AF-related symptoms
Documentation by a physician evaluating the patient that the patient experiences symptoms that could
be attributable to AF. This does not require a time-stamped ECG, Holter, or event monitor at the precise
time of symptoms. For patients with persistent AF who initially report no symptoms, it is reasonable to
reassess symptom status after restoration of sinus rhythm with cardioversion.
Minimum effectiveness
endpoint for patients with
symptomatic and
asymptomatic AF
The minimum effectiveness endpoint is freedom from symptomatic and asymptomatic episodes of AF/
AFL/AT recurrences at 12 months following ablation, free from antiarrhythmic drug therapy, and
including a prespeciﬁed blanking period.
Minimum chronic acceptable
success rate: paroxysmal AF
at 12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial, we
recommend that the minimum chronic acceptable success rate for paroxysmal AF at 12-month follow-
up is 50%.
Minimum chronic acceptable
success rate: persistent AF at
12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial, we
recommend that the minimum chronic acceptable success rate for persistent AF at 12-month follow-up
is 40%.
Minimum chronic acceptable
success rate:
long-standing persistent AF
at 12-month follow-up
If a minimum chronic success rate is selected as an objective effectiveness endpoint for a clinical trial, we
recommend that the minimum chronic acceptable success rate for long-standing persistent AF at
12-month follow-up is 30%.
Minimum follow-up screening
for paroxysmal AF recurrence
For paroxysmal AF, the minimum follow-up screening should include (1) 12-lead ECG at each follow-up
visit; (2) 24-hour Holter at the end of the follow-up period (e.g., 12 months); and (3) event recording
with an event monitor regularly and when symptoms occur from the end of the 3-month blanking period
to the end of follow-up (e.g., 12 months).
Minimum follow-up screening
for persistent or
long-standing AF recurrence
For persistent and long-standing persistent AF, the minimum follow-up screening should include (1)
12-lead ECG at each follow-up visit; (2) 24-hour Holter every 6 months; and (3) symptom-driven event
monitoring.
Requirements for
transesophageal
echocardiogram
It is recommended that the minimum requirement for performance of a TEE in a clinical trial should be
those requirements set forth in ACC/AHA/HRS 2014 Guidelines for AF Management pertaining to
anticoagulation at the time of cardioversion. Prior to undergoing an AF ablation procedure a TEE should
be performed in all patients with AF of .48 hours’ duration or of unknown duration if adequate
systemic anticoagulation has not been maintained for at least 3 weeks prior to AF ablation. If a TEE is
performed for this indication, it should be performed within 24 hours of the ablation procedure.
AF 5 atrial ﬁbrillation; DW-MRI 5 diffusion-weighted magnetic resonance imaging; CHF 5 congestive heart failure; QOL 5 quality of life; ECG 5 electro-
cardiogram; CABG 5 coronary artery bypass grafting; PV 5 pulmonary vein; SVC 5 superior vena cava; IVC 5 inferior vena cava; CFAE 5 complex fractionated
atrial electrogram; PVI5 pulmonary vein isolation; AFL5 atrial ﬂutter; AT5 atrial tachycardia; ACC5 American College of Cardiology; AHA5 American Heart
Association; HRS 5 Heart Rhythm Society.
*When reporting outcomes of AF ablation, the development of atrial tachycardia or atrial ﬂutter should be included in the broad deﬁnition of recurrence following
AF ablation. All studies should report freedom from AF, atrial tachycardia, and atrial ﬂutter. These endpoints can also be reported separately. All studies should
also clearly specify the type and frequency of ECG monitoring as well as the degree of compliance with the prespeciﬁed monitoring protocol.
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ECG monitoring tools (Table 6). This section also dis-
cusses the important topics of AAD and non-AAD use
prior to and following AF ablation, the role of cardiover-
sion, as well as the indications for and timing of repeat
AF ablation procedures.Section 9: Outcomes and Efﬁcacy
This section provides a comprehensive review of the out-
comes of catheter ablation of AF. Table 7 summarizes the
main ﬁndings of the most important clinical trials in thisﬁeld. Outcomes of AF ablation in subsets of patients not
well represented in these trials are reviewed. Outcomes
for speciﬁc ablation systems and strategies (CB ablation,
rotational activity ablation, and laser balloon ablation) are
also reviewed.Section 10: Complications
Catheter ablation of AF is one of the most complex inter-
ventional electrophysiological procedures. AF ablation by
its nature involves catheter manipulation and ablation in
the delicate thin-walled atria, which are in close proximity
Table 11 Quality-of-life scales, deﬁnitions, and strengths
Scale Deﬁnition/Details Strengths/Weaknesses
Short Form (36) Health
Survey (SF36)38
(General)
Consists of 8 equally weighted, scaled scores in the following
sections: vitality, physical functioning, bodily pain, general
health perceptions, physical role functioning, emotional role
functioning, social role functioning, mental health. Each
section receives a scale score from 0 to 100.
Physical component summary (PCS) and mental component
summary (MCS) is an average of all the physically and
mentally relevant questions, respectively.
The Short Form (12) Health Survey (SF12) is a shorter version of
the SF-36, which uses just 12 questions and still provides
scores that can be compared with SF-36 norms, especially for
summary physical and mental functioning.
Gives more precision in measuring QOL than EQ-5D but can be
harder to transform into cost utility analysis.
Advantages: extensively validated in a number
of disease and health states. Might have
more resolution than EQ-50 for AF QOL.
Disadvantages: not speciﬁc for AF, so might not
have resolution to detect AF-speciﬁc
changes in QOL.
EuroQol Five Dimensions
Questionnaire (EQ-5D)39
(General)
Two components: Health state description is measured in ﬁve
dimensions: mobility, self-care, usual activities, pain/
discomfort, anxiety/depression. Answers may be provided
on a three-level (3L) or ﬁve-level (5L) scale. In the
Evaluation section, respondents evaluate their overall
health status using a visual analogue scale (EQ-VAS).
Results can easily be converted to quality-adjusted life
years for cost utility analysis.
Advantages: extensively validated in a number
of disease and health states. Can easily be
converted into quality-adjusted life years for
cost-effectiveness analysis.
Disadvantages: might not be speciﬁc enough to
detect AF-speciﬁc changes in QOL. Might be
less speciﬁc than SF-36.
AF effect on Quality of Life
Survey (AFEQT)40
(AF speciﬁc)
20 questions: 4 targeting AF-related symptoms, 8 evaluating
daily function, and 6 assessing AF treatment concerns.
Each item scored on a 7-point Likert scale.
Advantages: brief, simple, very responsive to
AF interventions. Good internal validity and
well validated against a number of other
global and AF-speciﬁc QOL scales. Used in
CABANA.
Disadvantages: validation in only two
published studies (approximately 219
patients).
Quality of Life
Questionnaire for
Patients with AF
(AF-QoL)41
(AF speciﬁc)
18-item self-administered questionnaire with three domains:
psychological, physical, and sexual activity. Each item
scores on a 5-point Likert scale.
Advantages: brief, simple, responsive to AF
interventions; good internal validity; used in
SARA trial.
Disadvantages: external validity compared only
to SF-36; formal validation in 1 study
(approximately 400 patients).
Arrhythmia-Related
Symptom Checklist
(SCL)42 (AF speciﬁc)
16 items covering AF symptom frequency and symptom
severity.
Advantages: most extensively validated in a
number of arrhythmia cohorts and clinical
trials.
Disadvantages: time-consuming and uncertain
generalizability.
Mayo AF Speciﬁc Symptom
Inventory (MAFSI)43
(AF speciﬁc)
10 items covering AF symptom frequency and severity.
Combination of 5- point and 3-point Likert scale
responses.
Used in CABANA trial.
Advantages: validated in an AF ablation
population and responsive to ablation
outcome; used in CABANA trial.
Disadvantages: external validity compared only
to SF-36; 1 validation study (approximately
300 patients).
University of Toronto Atrial
Fibrillation Severity Scale
(AFSS) (AF speciﬁc)44
10 items covering frequency, duration, and severity. 7-point
Likert scale responses.
Advantages: validated and reproducible; used
in CTAF trial.
Disadvantages: time-consuming and uncertain
generalizability.
Arrhythmia Speciﬁc
Questionnaire in
Tachycardia and
Arrhythmia (ASTA)45
(AF speciﬁc)
Records number of AF episodes and average episode duration
during last 3 months. 8 symptoms and 2 disabling
symptoms are recorded with scores from 1–4 for each.
Advantages: validated in various arrhythmia
groups; external validity compared with SCL,
EQ5D, and SF-36; used in MANTRA-PAF; brief;
simple.
Disadvantages: one validation study
(approximately 300 patients).
European Heart Rhythm
Association (EHRA)46
(AF speciﬁc)
Like NYHA scale. I 5 no symptoms, II 5 mild symptoms not
affecting daily activity, III 5 severe symptoms affecting
daily activity, and IV 5 disabling symptoms terminating
daily activities.
Advantage: very simple, like NYHA.
Disadvantages: not used in studies and not well
validated; not very speciﬁc; unknown
generalizability.
(Continued )
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Table 11 (Continued )
Scale Deﬁnition/Details Strengths/Weaknesses
Canadian Cardiovascular
Society Severity of Atrial
Fibrillation Scale (CCS-
SAF)47 (AF speciﬁc)
Like NYHA scale. O 5 asymptomatic, I 5 AF symptoms have
minimal effect on patient’s QOL, II 5 AF symptoms have
minor effect on patient QOL, III 5 symptoms have
moderate effect on patient QOL, IV5 AF symptoms have
severe effect on patient QOL.
Advantages: very simple, like NYHA; validated
against SF-36 and University of Toronto
AFSS.
Disadvantages: poor correlation with subjective
AF burden; not very speciﬁc.
AF5 atrial ﬁbrillation; QOL5 quality of life; CABANA5 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation; SARA5 Study of Ablation
Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation; CTAF 5 Canadian Trial of Atrial Fibrillation; MANTRA-PAF 5 Medical ANtiarrhythmic Treatment or
Radiofrequency Ablation in Paroxysmal Atrial Fibrillation; NYHA 5 New York Heart Association; AFSS 5 atrial ﬁbrillation severity scale.
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impacted through collateral damage. It is therefore not sur-
prising that AF ablation is associated with a signiﬁcant risk
of complications, some of which might result in life-long
disability and/or death. This section reviews the complica-
tions associated with catheter ablation procedures per-
formed to treat AF. The types and incidence of
complications are presented, their mechanisms are
explored, and the optimal approach to prevention and treat-
ment is discussed (Tables 8 and 9).Section 11: Training Requirements
This section of the document outlines the training require-
ments for those who wish to perform catheter ablation of AF.Section 12: Surgical and Hybrid AF Ablation
Please refer to Table 2 and Figure 8 presented earlier in this
Executive Summary.Table 12 Non-AF recurrence–related endpoints for reporting in AF abla
Stroke and bleeding endpoints Deﬁnitions/Details
Stroke (2014 ACC/AHA Key Data
Elements)
An acute episode of focal or gl
vascular injury as a result o
hours, or if documented by
24 hours. Stroke may be cla
ischemic stroke), hemorrha
performed using the modiﬁ
Transient ischemic attack
(2014 ACC/AHA Key Data Elements)
Transient episode of focal neu
ischemia without acute inf
Major bleeding (ISTH deﬁnition) Fatal bleeding AND/OR sympt
intraspinal, intraocular, ret
compartment syndrome AN
2 g/dL (1.24 mmol/L) or m
Clinically relevant nonmajor bleed
(ISTH deﬁnition)
An acute or subacute clinicall
prompts a clinical response
bleeding; physician-guided
antithrombotic therapy (in
Minor bleeding (ISTH deﬁnition) All nonmajor bleeds. Minor bl
Incidence and discontinuation of oral
anticoagulation
The number of patients receiv
be documented at the end o
the number of patients disc
discontinuation of oral ant
proﬁle of the patients shou
AF 5 atrial ﬁbrillation; CT 5 computed tomography; MRI 5 magnetic resonanSection 13: Clinical Trial Design
Although there have been many advances made in the ﬁeld
of catheter and surgical ablation of AF, there is still much
to be learned about the mechanisms of initiation and main-
tenance of AF and how to apply this knowledge to the still-
evolving techniques of AF ablation. Although single-
center, observational reports have dominated the early
days of this ﬁeld, we are quickly moving into an era in
which hypotheses are put through the rigor of testing in
well-designed, randomized, multicenter clinical trials. It
is as a result of these trials that conventional thinking about
the best techniques, success rates, complication rates, and
long-term outcomes beyond AF recurrence—such as
thromboembolism and mortality—is being put to the test.
The ablation literature has also seen a proliferation of
meta-analyses and other aggregate analyses, which rein-
force the need for consistency in the approach to reporting
the results of clinical trials. This section reviews the mini-
mum requirements for reporting on AF ablation trials. It
also acknowledges the potential limitations of usingtion trials
obal neurological dysfunction caused by brain, spinal cord, or retinal
f hemorrhage or infarction. Symptoms or signs must persist 24
CT, MRI or autopsy, the duration of symptoms/signs may be less than
ssiﬁed as ischemic (including hemorrhagic transformation of
gic, or undetermined. Stroke disability measurement is typically
ed Rankin Scale (mRS).
rological dysfunction caused by brain, spinal cord, or retinal
arction and with signs and symptoms lasting less than 24 hours.
omatic bleeding in a critical area or organ, such as intracranial,
roperitoneal, intraarticular, pericardial, or intramuscular with
D/OR bleeding causing a fall in hemoglobin level of
ore, or leading to transfusion of two or more units of blood.
y overt bleed that does not meet the criteria for a major bleed but
such that it leads to one of the following: hospital admission for
medical or surgical treatment for bleeding; change in
cluding interruption or discontinuation).
eeds are further divided into clinically relevant and not.
ing oral anticoagulation and the type of oral anticoagulation should
f follow-up. If patients have their oral anticoagulation discontinued,
ontinuing, the timing of discontinuation, and the reasons for
icoagulation, as well as the clinical characteristics and stroke risk
ld be reported.
ce imaging.
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broad and consistent reporting of secondary outcomes to
assist the end-user in determining not only the scientiﬁc,
but also the clinical relevance of the results
(Tables 10–13).Unanswered Questions in AF Ablation
There is still much to be learned about the mechanisms of AF,
techniques of AF ablation, and long-term outcomes. The
following are unanswered questions for future investigation:
1. AF ablation and modiﬁcation of stroke risk and need for
ongoing oral anticoagulation (OAC): The CHA2DS2-
VASc score was developed for patients with clinical
AF. If a patient has received a successful ablation such
that he/she no longer has clinical AF (subclinical, or
no AF), then what is the need for ongoing OAC? Are
there any patients in whom successful ablation could
lead to discontinuation of OAC?
2. Substrate modiﬁcation in catheter-based management of
AF—particularly for persistent AF: What is the proper
lesion set required beyond pulmonary vein isolation?
Do lines and complex fractionated atrial electrogram
(CFAE) have any remaining role? Are these approaches
ill-advised or simply discouraged?
What is the role of targeting localized rotational acti-
vations? How do we ablate a localized rotational
activation? How can scar be characterized and targeted
for ablation? Do we need to replicate the MAZE pro-
cedure? Does the right atrium need to be targeted as
well as the left atrium?
3. Autonomic inﬂuence in AF: Is clinical AF really an auto-
nomicmediated arrhythmia? Is elimination of ganglionated
plexi required? Is there a role for autonomic modulation,
for example, spinal cord or vagal stimulation?
4. Contribution and modulation of risk factors on outcomes
of AF ablation: Obesity reduction has been shown to
reduce AF burden and recurrence in patients undergoing
ablation. What is the role of bariatric surgery? Does the
modulation of other risk factors inﬂuence outcome such
as hypertension, sleep apnea, and diabetes?
5. Outcomes in ablation of high-risk populations: Do high-
risk populations beneﬁt from AF ablation? Congestive
heart failure has been assessed in smaller trials, but larger
trials are required. Outcome data are needed in patients
with very enlarged LAs, hypertrophic cardiomyopathy,
patients with renal failure on dialysis, and the very
elderly.
6. Surgical vs catheter-based vs hybrid ablation: There
should be more comparative work between percuta-
neous and minimally invasive surgical approaches.
Both report similar outcomes, but there is a dearth
of comparative data. Is there any patient beneﬁt to
hybrid procedures?
7. How do we characterize patients who are optimal candi-
dates for ablation? Preablation late gadolinium-enhanced(LGE)-magnetic resonance imaging (MRI) might iden-
tify patients with heavy burdens of scar who are unlikely
to respond to ablation. These techniques must become
reproducible and reliable and must be assessed in multi-
center trials. Other markers need to be investigated,
including genetic markers, biochemical markers, and
clinical markers based on aggregated risk scores.
8. The incremental role of new technologies: As newer and
often more expensive technologies are produced for AF
ablation, their deﬁnitive incremental value must be deter-
mined in order to justify change in practice or case cost.
These technologies include global (basket) mapping
techniques, newer ablation indices for assessing lesion
durability, advanced imaging for viewing lesions in the
myocardium, etc. New energy sources, including laser,
low-intensity ultrasound, photonic particle therapy,
external beam ablation, and MRI-guided ablation, must
be assessed in comparative fashion.
9. Outcomes of AF ablation: We need to better understand
the clinical relevance of ablation outcomes. What is the
signiﬁcance of time to recurrence of 30 seconds of
arrhythmia? How do we best quantify AF burden?
How do these outcomes relate to quality of life and
stroke risk?
10. What is the role of surgical LA reduction? Does left atrial
appendage (LAA) occlusion or obliteration improve
outcome of persistent AF ablation with an accompa-
nying reduction in stroke? Does ablation work through
atrial size reduction? What is the incidence of “stiff
atrial” syndrome and does this mitigate the clinical
impact of ablation?
11. Working in teams: What is the role of the entire heart
team in AF ablation? Does a team approach achieve bet-
ter outcomes than a “silo” approach?
12. Improving the safety of catheter ablation: As ablation ex-
tends to more operators and less experienced operators,
the statistical occurrence of complications will increase.
We need newer techniques to minimize complications
and institute standards for operators to improve the
reproducibility of ablation results and safety proﬁles at
a variety of centers worldwide.
13. How does catheter ablation affect mortality, stroke, and
hospitalization in broad and selected patient populations
receiving catheter ablation for AF?
14. Management of patients who fail initial attempts at cath-
eter ablation: Should there be speciﬁc criteria for repeat
ablations (e.g., atrial size, body mass index)? Should pa-
tients be referred for surgery for repeat ablation?
In order to address these and other important questions
in the ﬁeld of catheter and surgical AF ablation, we urge
investigators to create and participate in multisite collab-
orations and electrophysiology research networks with
involvement of senior and junior investigators on the
steering committees to push forward the next phase of
AF research. We also urge funding bodies to support
these important initiatives.
Table 13 Advantages and disadvantages of AF-related endpoints in AF ablation trials
Endpoint Advantages Disadvantages Relevance and Comments
Freedom from AF/AFL/AT recurrence
“gold standard” is 30 seconds - Has been in use for many years
- Can be used to compare results of new
trials with historical trials
- Sets a high bar for AF elimination
- Can systematically underestimate the
efﬁcacy of AF ablation, particularly for
persistent AF, if 30-second cutoff is used
- Particularly well suited for
paroxysmal AF outcomes
- Reporting of cutoffs other than
30 seconds encouraged as
secondary endpoints to better
contextualize results
- May be reported as proportion
of patients free from arrhythmia
or time to recurrence
Freedom from stroke-relevant AF/
AFL/AT-duration cutoff of 1 hour
- Useful for trials in which interest is
more for prognostic change conferred
by ablation rather than elimination of
all arrhythmias
- No consistent deﬁnition of what a stroke-
relevant duration of AF is: ranges from 6
minutes to 24 hours in literature
- More than 1 hour could be a
useful cutoff based on results of
505 trial
- May be reported as proportion
of patients free from arrhythmia
or time to recurrence
Freedom from AF/AFL/AT requiring
intervention (emergency visits,
cardioversion, urgent care visit,
reablation, etc.)
- Can provide an endpoint more relevant
to systemic costs of AF recurrence
- Clinically relevant
- Will overestimate efﬁcacy of ablation by
ignoring shorter episodes not requiring
intervention that still might be important
to quality of life or stroke
- Determination of what is an
“intervention” must be
prespeciﬁed in protocol and
biases mitigated to avoid over-
or underintervention in the trial
Freedom from persistent AF/AFL/AT-
duration cutoff of 7 days
- Useful for trials assessing additional
substrate modiﬁcation in persistent AF
- Can systematically overestimate the
efﬁcacy of AF ablation, particularly for
persistent AF
- Can require continuous
monitoring to deﬁnitively
assess if episode is .7 days
Freedom from AF/AFL/AT on
previously ineffective
antiarrhythmic therapy
- If patient maintains sinus rhythm on
previously ineffective drug therapy,
this may be considered a clinically
relevant, successful outcome
- Will increase the success rate compared
with off-drug success
- May not be relevant to patients hoping to
discontinue drug therapy
- Postablation drug and dosage
of drug should be identical to
preablation drug and dosage
Signiﬁcant reduction in AF burden:
.75% reduction from pre- to
postablation and/or total
postablation burden ,12%
- Can be useful in persistent AF studies,
but might not be suited for early,
paroxysmal AF studies
- Ideally requires continuous monitoring
using an implantable device
- No scientiﬁc basic exists showing that a
75% reduction in AF burden impacts hard
endpoints, including heart failure, stroke,
and mortality
- AF burden can be estimated by
intermittent monitoring and
reporting of patient symptoms
and recurrences like a “time in
therapeutic range” report for
oral anticoagulation; see text
- Could also see 75% reduction in
number and duration of AF
episodes
- Because there is no ﬁrm
scientiﬁc basis for selecting the
cutoff of 75%, this prior
recommendation is provided
only as an example of what
future clinical trials may choose
to use as a deﬁnition of clinical/
partial success
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Prevention in AF progression: time
to ﬁrst episode of persistent
AF (.7 days)
- Does not assume that total
elimination of AF is required
- Well suited for paroxysmal or “early”
AF studies in which goal is to prevent
progression to persistent AF
- Prevention in progression might be
irrelevant for stroke or thromboembolic
outcomes
- Long follow-up time might be required
unless population is “enriched”
- Can ideally require continuous
implantable monitoring
- Might be useful for speciﬁc
populations such as heart
failure or hypertrophic
cardiomyopathy, in which
progression to persistent AF can
lead to increased
hospitalization
Regression of AF: reduction in burden
to a given threshold or conversion
of persistent to paroxysmal AF
- Does not assume that total
elimination of AF is required
- Well suited for persistent “late” AF
studies in which goal is to regress to
paroxysmal AF, which might be easier
to control with drug therapy
- Regression endpoint will overestimate
efﬁcacy of AF ablation
- Might ideally require continuous
implantable monitoring
- Patients will require ongoing drug therapy
- Could be particularly useful for
long-standing persistent AF
populations with structural
heart disease, heart failure, etc.
Acute AF termination during ablation
procedure
- Could provide indication of successful
modiﬁcation of substrate responsible
for maintaining AF, most relevant to
persistent or long-standing persistent
AF
- Limited studies have linked acute AF
termination to long-term success
- Relevance of acute AF termination has not
consistently been shown to correlate to
long-term success
- Endpoint might not be relevant to
paroxysmal AF patients in whom AF might
terminate spontaneously
- Some studies employ administration of
intravenous or oral antiarrhythmics
during ablation that could cause
spontaneous termination
- Studies consider termination as reversion
to sinus rhythm, whereas others consider
reversion to any regular tachycardia as
termination
- Intraprocedural administration
of preprocedural oral
antiarrhythmics or
intraprocedural intravenous
antiarrhythmics are
discouraged
- If antiarrhythmics are used,
their use and dosage before and
during the ablation should be
clearly documented
- Termination to sinus rhythm
and termination to another
regular tachycardia (AT or AFL)
should be separately reported
AF 5 atrial ﬁbrillation; AFL 5 atrial ﬂutter; AT 5 atrial tachycardia.
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Catheter ablation of AF is a very commonly performed pro-
cedure in hospitals throughout the world. This document pro-
vides an up-to-date review of the indications, techniques, and
outcomes of catheter and surgical ablation of AF. Areas for
which a consensus can be reached concerning AF ablation
are identiﬁed, and a series of consensus deﬁnitions have
been developed for use in future clinical trials of AF ablation.
Also included within this document are recommendations
concerning indications for AF ablation, technical perfor-
mance of this procedure, and training. It is our hope to
improve patient care by providing a foundation for those
involved with care of patients with AF as well as those
who perform AF ablation. It is recognized that this ﬁeld con-
tinues to evolve rapidly and that this document will need to be
updated. Successful AF ablation programs optimally should
consist of a cooperative team of cardiologists, electrophysiol-
ogists, and surgeons to ensure appropriate indications, pro-
cedure selection, and follow-up.Acknowledgments
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